


PRODUCT INFORMATION



(±)-JWH 398 N-(4-hydroxypentyl) metabolite-d₅

Item No. 14370

CAS Registry No.: 2747914-17-4
Formal Name: (4-chloronaphthalen-1-yl)
(1-(4-hydroxypentyl)-1H-indol-3-yl-
2,4,5,6,7-d₅)methanone
MF: C₂₄H₁₇ClD₅NO₂
FW: 396.9
Chemical Purity: ≥98% (JWH 398 N-(4-hydroxypentyl)
metabolite)
**Deuterium
Incorporation:** ≥99% deuterated forms (d₁-d₅); ≤1% d₀
UV/Vis.: λ_{max}: 219, 316 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

(±)-JWH 398 N-(4-hydroxypentyl) metabolite-d₅ (Item No. 14370) is intended for use as an internal standard for the quantification of JWH 398 N-(4-hydroxypentyl) metabolite (Item No. 10943) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

JWH 398 (Item No. 13636) is a synthetic cannabinoid (CB) that activates both central CB₁ and peripheral CB₂ receptors (K_i = 2.3 and 2.8 nM, respectively).¹ It has been reported to be an adulterant of herbal products.^{2,3} (±)-JWH 398 N-(4-hydroxypentyl) metabolite is an expected phase I metabolite of JWH 398 (Item No. 13636), detectable in serum and urine. While similar hydroxylated phase I metabolites of synthetic CBs retain activity, the physiological properties of this compound have yet to be determined.^{4,5} This product is intended for research and forensic applications.

References

1. Huffman, J.W. The cannabinoid receptors Cannabimimetic indoles, pyrroles, and indenes: Structure-activity relationships and receptor interactions. *The cannabinoid receptors*. Reggio, P. H., editor, Humana Press (2009).
2. Kikura-Hanajiri, R., Uchiyama, N., and Goda, Y. Survey of current trends in the abuse of psychotropic substances and plants in Japan. *Leg. Med. (Tokyo)* **13(3)**, 109-15 (2011).
3. Dresen, S., Ferreirós, N., Pütz, M., et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. *J. Mass Spectrom.* **45(10)**, 1186-94 (2010).
4. Brents, L.K., Reichard, E.E., Zimmerman, M., et al. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain *in vitro* and *in vivo* cannabinoid 1 receptor affinity and activity. *PLoS One* **6(7)**, e21917 (2011).
5. Brents, L.K., Gallus-Zawala, A., Radomska-Pandya, A., et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. *Biochem. Pharmacol.* **83(7)**, 952-961 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/14/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM